Climb Bio partner Mabworks doses first patient in China Phase 2 IgA nephropathy trial

PUBT · 1d ago
Climb Bio partner Mabworks doses first patient in China Phase 2 IgA nephropathy trial
  • A Phase 2 trial in China dosed its first patient with immunoglobulin A nephropathy in a study run with Climb Bio.
  • No clinical results were reported; the update signals the program has moved into active patient treatment.
  • Beijing Mabworks announced the milestone on Aug. 13, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-350596), on August 14, 2026, and is solely responsible for the information contained therein.